Lipocine Inc (LPCN)

$2.04 -0.01 (-0.49%)
Market Cap 16.90M
Revenue (ttm) 1.98M
Net Income (ttm) -9.63M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -486.36%
Debt to Equity Ratio 0.00
Volume 95,800
Avg Vol 468,992
Day's Range N/A - N/A
Shares Out 8.24M
Stochastic %K 0%
Beta 0.48
Analysts Hold
Price Target $6.00

Company Profile

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. The company offers TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. It also develops LPCN 1154 (BRLIZIO), an oral neuro-steroid in a Phase 3 pivotal trial for postpartum depression; LPCN 1148, a prodrug of testosterone and testosterone laurate that has completed a Phase 2 trial for the ma...

Industry: Biotechnology
Sector: Healthcare
Phone: 801 994 7383
Fax: 801 994 7388
Address:
675 Arapeen Drive, Suite 202, Salt Lake City, United States
brunoq14
brunoq14 Jun. 5 at 4:19 AM
$LPCN Frankly, I am not looking forward to overseeing the progress of 1154 a second time, after being under the false impression that everything was practically perfect the first time. I do realize however that a second chance in this kind of affair is pretty darned unusual, so I will welcome it with bated breath.
1 · Reply
veseli
veseli Jun. 4 at 8:50 PM
$LPCN managment didn't deserve a penny... F u Patel and rest of your incompetent team that is not able to make a profit for 5 years with product you have while being crap in developing new ones .
0 · Reply
amazingcrwns
amazingcrwns Jun. 4 at 12:44 PM
$LPCN I always enjoy these KOL presentations. I'm looking forward to hearing their outlook on 1154. https://ir.lipocine.com/2026-06-04-Lipocine-Inc-to-Host-Virtual-KOL-Event-Highlighting-Unmet-Needs-in-Postpartum-Depression-and-the-Clinical-Profile-of-LPCN-1154
1 · Reply
AtariLynx
AtariLynx Jun. 3 at 6:43 PM
$LPCN I added
0 · Reply
xelrose
xelrose Jun. 3 at 7:59 AM
$LPCN 60 days from BTD and Fast Track request are gone. Answer should be at LPCN now. Or am i wrong?
1 · Reply
brunoq14
brunoq14 Jun. 3 at 3:10 AM
$LPCN One problem with the rogue site story is that the company running the trial is legally responsible for clinical monitoring of the trial sites, to ensure that the protocol is being followed. This is typically done by CROs, Contract Research Organizations. So how did a "rogue site" happen? Several people in this group appear to have not received the drug in question at all!
1 · Reply
amazingcrwns
amazingcrwns Jun. 1 at 6:35 PM
$LPCN I think the epidemiologic outlier site data is convincing. I love the data when you exclude that site, I believe the FDA will agree to a validation study and those results will lead to business development interest. Its going to take time to get there, and they still need to fet FDA alignment on the path forward. I'm expecting sideways trading until they get that alignment, (unless something unexpected happens like BTD) and then a slow climb back up as they start hitting milestones in the trial. (1st dosing, interim readout, complete enrollment, LPLV etc.)
1 · Reply
LQQKER_INSIDER
LQQKER_INSIDER Jun. 1 at 4:04 PM
$VRRM $ZS $LPCN $WOOF $LYFT I REPEAT, HOW AM I DOING DO FAR? THESE 3-DAY RETURNS GOOD??? 💋 When I see most peeps posting 5-tickers, they're all small-cap trash🗑stocks. Check the results a week later and their best performing one is down (25%). 😹 LQQKER is the opposite of that. 🔎
0 · Reply
LQQKER_INSIDER
LQQKER_INSIDER Jun. 1 at 2:15 PM
$LPCN 🚀 🚀 🚀 MOON ME LIKE ELON, BABY! 💋
0 · Reply
amazingcrwns
amazingcrwns May. 31 at 4:13 PM
$LPCN for anyone that may have missed it. The A.G.P. Annual Virtual Healthcare Company Showcase fireside chat is now available on the presentations page of the company website. https://ir.lipocine.com/presentations
0 · Reply
Latest News on LPCN
Lipocine Inc. to Host Virtual KOL Event Highlighting Unmet Needs in Postpartum Depression and the Clinical Profile of LPCN 1154

Jun 4, 2026, 8:00 AM EDT - 4 days ago

Lipocine Inc. to Host Virtual KOL Event Highlighting Unmet Needs in Postpartum Depression and the Clinical Profile of LPCN 1154

Lipocine Transcript: A.G.P.'s Annual Virtual Healthcare Conference

May 20, 2026, 3:00 PM EDT - 19 days ago

Lipocine Transcript: A.G.P.'s Annual Virtual Healthcare Conference

Lipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual Meeting

May 19, 2026, 8:00 AM EDT - 20 days ago

Lipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual Meeting

Anaveon Strengthens Leadership Team with Appointments of Eric Zanelli as Chief Scientific Officer and Jill Jene as Chief Business Officer

May 19, 2026, 4:00 AM EDT - 20 days ago

Anaveon Strengthens Leadership Team with Appointments of Eric Zanelli as Chief Scientific Officer and Jill Jene as Chief Business Officer

Lipocine to Present at A.G.P.'s Annual Virtual Healthcare Company Showcase

May 18, 2026, 8:00 AM EDT - 21 days ago

Lipocine to Present at A.G.P.'s Annual Virtual Healthcare Company Showcase

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026

May 7, 2026, 4:05 PM EDT - 4 weeks ago

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026

Lipocine Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 4 weeks ago

Lipocine Quarterly report: Q1 2026

Lipocine Earnings release: Q1 2026

May 7, 2026, 7:00 AM EDT - 4 weeks ago

Lipocine Earnings release: Q1 2026

Lipocine Slides: Corporate presentation

May 7, 2026, 7:00 AM EDT - 4 weeks ago

Lipocine Slides: Corporate presentation

Lipocine Proxy statement: Proxy filing

Apr 21, 2026, 8:00 AM EDT - 6 weeks ago

Lipocine Proxy statement: Proxy filing

Lipocine Proxy statement: Proxy filing

Apr 21, 2026, 8:00 AM EDT - 6 weeks ago

Lipocine Proxy statement: Proxy filing

Lipocine price target lowered to $6 from $11 at Alliance Global

2026-04-13T18:12:07.000Z - 2 months ago

Lipocine price target lowered to $6 from $11 at Alliance Global

Lipocine Slides: Investor presentation

Apr 13, 2026, 7:00 AM EDT - 2 months ago

Lipocine Slides: Investor presentation

Lipocine Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Apr 6, 2026, 7:56 AM EDT - 2 months ago

Lipocine Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Lipocine downgraded to Neutral from Buy at H.C. Wainwright

2026-04-06T10:16:57.000Z - 2 months ago

Lipocine downgraded to Neutral from Buy at H.C. Wainwright

Lipocine’s LPCN 1154 did not meet endpoint in postpartum depression trial

2026-04-02T12:07:46.000Z - 2 months ago

Lipocine’s LPCN 1154 did not meet endpoint in postpartum depression trial

Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum Depression

Apr 2, 2026, 8:00 AM EDT - 2 months ago

Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum Depression

Lipocine Slides: Corporate presentation

Apr 2, 2026, 7:00 AM EDT - 2 months ago

Lipocine Slides: Corporate presentation

Lipocine price target raised to $11 from $6.75 at Alliance Global

2026-03-17T16:00:59.000Z - 2 months ago

Lipocine price target raised to $11 from $6.75 at Alliance Global

Lipocine Announces Financial Results for the Full Year Ended December 31, 2025

Mar 10, 2026, 8:00 AM EDT - 3 months ago

Lipocine Announces Financial Results for the Full Year Ended December 31, 2025

Lipocine Earnings release: Q4 2025

Mar 10, 2026, 7:00 AM EDT - 3 months ago

Lipocine Earnings release: Q4 2025

Lipocine Annual report: Q4 2025

Mar 10, 2026, 7:00 AM EDT - 3 months ago

Lipocine Annual report: Q4 2025

Lipocine announces last patient visit in Phase 3 trial of LPCN 1154

2026-02-18T13:05:35.000Z - 3 months ago

Lipocine announces last patient visit in Phase 3 trial of LPCN 1154

Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD)

Feb 18, 2026, 8:00 AM EST - 3 months ago

Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD)

Lipocine Slides: Corporate presentation

Feb 18, 2026, 6:00 AM EST - 3 months ago

Lipocine Slides: Corporate presentation

Lipocine price target raised to $15 from $7 at H.C. Wainwright

2026-01-21T11:15:46.000Z - 4 months ago

Lipocine price target raised to $15 from $7 at H.C. Wainwright

Lipocine completes enrollment, dosing in Phase 3 trial of LPCN 1154

2026-01-20T13:05:41.000Z - 4 months ago

Lipocine completes enrollment, dosing in Phase 3 trial of LPCN 1154

Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)

Jan 20, 2026, 8:00 AM EST - 4 months ago

Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)

Lipocine: DSMB recommended Phase 3 LPCN 1154 continue as planned

2026-01-12T13:16:24.000Z - 5 months ago

Lipocine: DSMB recommended Phase 3 LPCN 1154 continue as planned

Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)

Jan 12, 2026, 8:00 AM EST - 5 months ago

Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)

Lipocine ‘s PPD Phase 3 study hits 80% enrollment milestone

2025-12-16T13:06:09.000Z - 6 months ago

Lipocine ‘s PPD Phase 3 study hits 80% enrollment milestone

Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone

Dec 16, 2025, 8:00 AM EST - 6 months ago

Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone

Lipocine reports ‘promising’ safety profile in Phase 3 trial of LPCN 1154

2025-11-18T14:44:20.000Z - 7 months ago

Lipocine reports ‘promising’ safety profile in Phase 3 trial of LPCN 1154

Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)

Nov 18, 2025, 8:00 AM EST - 7 months ago

Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)

Lipocine price target lowered to $7 from $8 at H.C. Wainwright

2025-11-13T11:20:38.000Z - 7 months ago

Lipocine price target lowered to $7 from $8 at H.C. Wainwright

Lipocine reports Q3 EPS (59c) vs. (44c) last year

2025-11-06T13:06:28.000Z - 7 months ago

Lipocine reports Q3 EPS (59c) vs. (44c) last year

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025

Nov 6, 2025, 8:00 AM EST - 7 months ago

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025

Lipocine Earnings release: Q3 2025

Nov 6, 2025, 7:00 AM EST - 7 months ago

Lipocine Earnings release: Q3 2025

Lipocine Quarterly report: Q3 2025

Nov 6, 2025, 7:00 AM EST - 7 months ago

Lipocine Quarterly report: Q3 2025

Lipocine Presents LPCN 2401 Clinical Data at ObesityWeek®

Nov 4, 2025, 8:00 AM EST - 7 months ago

Lipocine Presents LPCN 2401 Clinical Data at ObesityWeek®

Lipocine provides update on Phase 3 clinical trial in postpartum depression

2025-09-30T12:10:40.000Z - 8 months ago

Lipocine provides update on Phase 3 clinical trial in postpartum depression

Lipocine Provides Progress Update on LPCN 1154 Phase 3 Clinical Trial in Postpartum Depression (PPD)

Sep 30, 2025, 8:00 AM EDT - 8 months ago

Lipocine Provides Progress Update on LPCN 1154 Phase 3 Clinical Trial in Postpartum Depression (PPD)

Lipocine to Present at H.C. Wainwright 27th Annual Global Investment Conference

Sep 5, 2025, 4:30 PM EDT - 9 months ago

Lipocine to Present at H.C. Wainwright 27th Annual Global Investment Conference

Lipocine Announces LPCN 2101 Abstracts Accepted for Presentation at AES 2025

Aug 26, 2025, 8:00 AM EDT - 10 months ago

Lipocine Announces LPCN 2101 Abstracts Accepted for Presentation at AES 2025

Lipocine reports Q2 EPS (41c) vs. (57c) last year

2025-08-05T12:05:16.000Z - 10 months ago

Lipocine reports Q2 EPS (41c) vs. (57c) last year

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2025

Aug 5, 2025, 8:00 AM EDT - 10 months ago

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2025

Lipocine Quarterly report: Q2 2025

Aug 5, 2025, 6:00 AM EDT - 10 months ago

Lipocine Quarterly report: Q2 2025

Lipocine Earnings release: Q2 2025

Aug 5, 2025, 6:00 AM EDT - 10 months ago

Lipocine Earnings release: Q2 2025

Lipocine Transcript: Status Update

Jul 9, 2025, 11:00 AM EDT - 11 months ago

Lipocine Transcript: Status Update

Lipocine says first patient dosed in Phase 3 clinical trial of LPCN 1154

2025-06-26T12:05:39.000Z - 1 year ago

Lipocine says first patient dosed in Phase 3 clinical trial of LPCN 1154

Lipocine Announces First Patient Dosed in Phase 3 Clinical Trial for LPCN 1154 in Postpartum Depression

Jun 26, 2025, 8:00 AM EDT - 1 year ago

Lipocine Announces First Patient Dosed in Phase 3 Clinical Trial for LPCN 1154 in Postpartum Depression

Lipocine to Host Virtual R&D Investor Event to Discuss LPCN 1154 (BRLIZIO™) as a Treatment for Postpartum Depression on July 9, 2025

Jun 23, 2025, 8:00 AM EDT - 1 year ago

Lipocine to Host Virtual R&D Investor Event to Discuss LPCN 1154 (BRLIZIO™) as a Treatment for Postpartum Depression on July 9, 2025

Lipocine announces filing of NDA for TLANDO in Canada

2025-06-09T12:10:36.000Z - 1 year ago

Lipocine announces filing of NDA for TLANDO in Canada

Lipocine Announces Filing of New Drug Submission for TLANDO® in Canada

Jun 9, 2025, 8:00 AM EDT - 1 year ago

Lipocine Announces Filing of New Drug Submission for TLANDO® in Canada

Lipocine assumed with a Buy at H.C. Wainwright

2025-05-29T14:45:19.000Z - 1 year ago

Lipocine assumed with a Buy at H.C. Wainwright

Lipocine's LPCN 1148 Highlighted in the June 2025 Edition of Hepatology

May 22, 2025, 8:00 AM EDT - 1 year ago

Lipocine's LPCN 1148 Highlighted in the June 2025 Edition of Hepatology

Lipocine Transcript: A.G.P.'s Virtual Healthcare Company Showcase 2025

May 21, 2025, 4:00 PM EDT - 1 year ago

Lipocine Transcript: A.G.P.'s Virtual Healthcare Company Showcase 2025

Lipocine to Present at A.G.P.'s Annual Healthcare Company Showcase

May 14, 2025, 8:00 AM EDT - 1 year ago

Lipocine to Present at A.G.P.'s Annual Healthcare Company Showcase

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2025

Lipocine Earnings release: Q1 2025

May 8, 2025, 12:00 AM EDT - 1 year ago

Lipocine Earnings release: Q1 2025

Lipocine Quarterly report: Q1 2025

May 8, 2025, 12:00 AM EDT - 1 year ago

Lipocine Quarterly report: Q1 2025

Lipocine announces license and supply agreement with Ache

2025-05-06T12:17:57.000Z - 1 year ago

Lipocine announces license and supply agreement with Ache

Lipocine Announces License and Supply Agreement for TLANDO® in Brazil

May 6, 2025, 8:00 AM EDT - 1 year ago

Lipocine Announces License and Supply Agreement for TLANDO® in Brazil

Lipocine Proxy statement: Proxy Filing

Apr 22, 2025, 8:00 AM EDT - 1 year ago

Lipocine Proxy statement: Proxy Filing

Lipocine Proxy statement: Proxy Filing

Apr 10, 2025, 8:00 AM EDT - 1 year ago

Lipocine Proxy statement: Proxy Filing

Lipocine initiates Phase 3 trial for LPCN 1154

2025-03-26T12:06:51.000Z - 1 year ago

Lipocine initiates Phase 3 trial for LPCN 1154

Lipocine Announces Initiation of Outpatient Phase 3 Postpartum Depression Trial of LPCN 1154

Mar 26, 2025, 8:00 AM EDT - 1 year ago

Lipocine Announces Initiation of Outpatient Phase 3 Postpartum Depression Trial of LPCN 1154

Lipocine price target lowered to $6.75 from $10 at Alliance Global Partners

2025-03-19T11:05:23.000Z - 1 year ago

Lipocine price target lowered to $6.75 from $10 at Alliance Global Partners

Lipocine Earnings release: Q4 2024

Mar 13, 2025, 11:30 AM EDT - 1 year ago

Lipocine Earnings release: Q4 2024

Lipocine Annual report: Q4 2024

Mar 13, 2025, 11:30 AM EDT - 1 year ago

Lipocine Annual report: Q4 2024

Lipocine Announces Financial Results for the Full Year Ended December 31, 2024

Mar 13, 2025, 8:00 AM EDT - 1 year ago

Lipocine Announces Financial Results for the Full Year Ended December 31, 2024

Lipocine Announces FDA Labeling Changes for Testosterone Products

Mar 12, 2025, 8:00 AM EDT - 1 year ago

Lipocine Announces FDA Labeling Changes for Testosterone Products

Lipocine Receives Updated Regulatory Guidance on LPCN 1154

Feb 6, 2025, 8:00 AM EST - 1 year ago

Lipocine Receives Updated Regulatory Guidance on LPCN 1154

FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis

Dec 17, 2024, 8:00 AM EST - 1 year ago

FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis

Lipocine Press release: Corporate Presentation

Dec 12, 2024, 7:00 PM EST - 1 year ago

Lipocine Press release: Corporate Presentation

Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor's Cut Session

Nov 18, 2024, 8:00 AM EST - 1 year ago

Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor's Cut Session

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2024

Nov 7, 2024, 8:00 AM EST - 1 year ago

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2024

Lipocine Quarterly report: Q3 2024

Nov 6, 2024, 6:00 PM EST - 1 year ago

Lipocine Quarterly report: Q3 2024

Lipocine Earnings release: Q3 2024

Nov 6, 2024, 6:00 PM EST - 1 year ago

Lipocine Earnings release: Q3 2024

Lipocine Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO® in South Korea

Oct 31, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO® in South Korea

Lipocine Transcript: Status Update

Oct 15, 2024, 6:00 PM EDT - 1 year ago

Lipocine Transcript: Status Update

Lipocine Slides: Status Update

Oct 15, 2024, 6:00 PM EDT - 1 year ago

Lipocine Slides: Status Update

Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results

Oct 10, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results

Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize TLANDO® in the Gulf Cooperation Council (GCC) Countries

Oct 8, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize TLANDO® in the Gulf Cooperation Council (GCC) Countries

Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024

Oct 2, 2024, 8:00 AM EDT - 1 year ago

Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024

Lipocine to Present at H.C. Wainwright 8th Annual MASH Investor Conference

Sep 30, 2024, 8:00 AM EDT - 1 year ago

Lipocine to Present at H.C. Wainwright 8th Annual MASH Investor Conference

Lipocine Announces Phase 2 Data on LPCN 2401 to be Presented at ObesityWeek®

Sep 5, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces Phase 2 Data on LPCN 2401 to be Presented at ObesityWeek®

Lipocine to Present at H.C. Wainwright 26th Annual Global Investment Conference

Aug 27, 2024, 8:00 AM EDT - 1 year ago

Lipocine to Present at H.C. Wainwright 26th Annual Global Investment Conference

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2024

Aug 8, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2024

Lipocine Quarterly report: Q2 2024

Aug 7, 2024, 6:00 PM EDT - 1 year ago

Lipocine Quarterly report: Q2 2024

Lipocine Earnings release: Q2 2024

Aug 7, 2024, 6:00 PM EDT - 1 year ago

Lipocine Earnings release: Q2 2024

Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study

Jun 25, 2024, 8:00 AM EDT - 2 years ago

Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study

Lipocine Presents 52 Week Results from LPCN 1148 Phase 2 Study in Late Breaking Session at EASL Congress 2024

Jun 10, 2024, 8:00 AM EDT - 2 years ago

Lipocine Presents 52 Week Results from LPCN 1148 Phase 2 Study in Late Breaking Session at EASL Congress 2024

Lipocine Proxy statement: Proxy Filing

Jun 3, 2024, 8:00 AM EDT - 2 years ago

Lipocine Proxy statement: Proxy Filing

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024

May 9, 2024, 8:00 AM EDT - 2 years ago

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024

Lipocine Quarterly report: Q1 2024

May 8, 2024, 6:00 PM EDT - 2 years ago

Lipocine Quarterly report: Q1 2024

Lipocine Earnings release: Q1 2024

May 8, 2024, 6:00 PM EDT - 2 years ago

Lipocine Earnings release: Q1 2024

Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024

May 8, 2024, 8:00 AM EDT - 2 years ago

Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024

Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154

May 1, 2024, 8:00 AM EDT - 2 years ago

Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154

Lipocine Registration statement: Registration Filing

Apr 23, 2024, 8:00 AM EDT - 2 years ago

Lipocine Registration statement: Registration Filing

Lipocine Proxy statement: Proxy Filing

Apr 23, 2024, 8:00 AM EDT - 2 years ago

Lipocine Proxy statement: Proxy Filing

Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity

Apr 11, 2024, 7:00 AM EDT - 2 years ago

Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity

Lipocine Transcript: Study Result

Apr 10, 2024, 6:00 PM EDT - 2 years ago

Lipocine Transcript: Study Result

Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis

Mar 28, 2024, 8:00 AM EDT - 2 years ago

Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis

Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154

Mar 25, 2024, 8:00 AM EDT - 2 years ago

Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154

Lipocine Announces Financial Results for the Full Year Ended December 31, 2023

Mar 7, 2024, 8:00 AM EST - 2 years ago

Lipocine Announces Financial Results for the Full Year Ended December 31, 2023

brunoq14
brunoq14 Jun. 5 at 4:19 AM
$LPCN Frankly, I am not looking forward to overseeing the progress of 1154 a second time, after being under the false impression that everything was practically perfect the first time. I do realize however that a second chance in this kind of affair is pretty darned unusual, so I will welcome it with bated breath.
1 · Reply
veseli
veseli Jun. 4 at 8:50 PM
$LPCN managment didn't deserve a penny... F u Patel and rest of your incompetent team that is not able to make a profit for 5 years with product you have while being crap in developing new ones .
0 · Reply
amazingcrwns
amazingcrwns Jun. 4 at 12:44 PM
$LPCN I always enjoy these KOL presentations. I'm looking forward to hearing their outlook on 1154. https://ir.lipocine.com/2026-06-04-Lipocine-Inc-to-Host-Virtual-KOL-Event-Highlighting-Unmet-Needs-in-Postpartum-Depression-and-the-Clinical-Profile-of-LPCN-1154
1 · Reply
AtariLynx
AtariLynx Jun. 3 at 6:43 PM
$LPCN I added
0 · Reply
xelrose
xelrose Jun. 3 at 7:59 AM
$LPCN 60 days from BTD and Fast Track request are gone. Answer should be at LPCN now. Or am i wrong?
1 · Reply
brunoq14
brunoq14 Jun. 3 at 3:10 AM
$LPCN One problem with the rogue site story is that the company running the trial is legally responsible for clinical monitoring of the trial sites, to ensure that the protocol is being followed. This is typically done by CROs, Contract Research Organizations. So how did a "rogue site" happen? Several people in this group appear to have not received the drug in question at all!
1 · Reply
amazingcrwns
amazingcrwns Jun. 1 at 6:35 PM
$LPCN I think the epidemiologic outlier site data is convincing. I love the data when you exclude that site, I believe the FDA will agree to a validation study and those results will lead to business development interest. Its going to take time to get there, and they still need to fet FDA alignment on the path forward. I'm expecting sideways trading until they get that alignment, (unless something unexpected happens like BTD) and then a slow climb back up as they start hitting milestones in the trial. (1st dosing, interim readout, complete enrollment, LPLV etc.)
1 · Reply
LQQKER_INSIDER
LQQKER_INSIDER Jun. 1 at 4:04 PM
$VRRM $ZS $LPCN $WOOF $LYFT I REPEAT, HOW AM I DOING DO FAR? THESE 3-DAY RETURNS GOOD??? 💋 When I see most peeps posting 5-tickers, they're all small-cap trash🗑stocks. Check the results a week later and their best performing one is down (25%). 😹 LQQKER is the opposite of that. 🔎
0 · Reply
LQQKER_INSIDER
LQQKER_INSIDER Jun. 1 at 2:15 PM
$LPCN 🚀 🚀 🚀 MOON ME LIKE ELON, BABY! 💋
0 · Reply
amazingcrwns
amazingcrwns May. 31 at 4:13 PM
$LPCN for anyone that may have missed it. The A.G.P. Annual Virtual Healthcare Company Showcase fireside chat is now available on the presentations page of the company website. https://ir.lipocine.com/presentations
0 · Reply
LQQKER_INSIDER
LQQKER_INSIDER May. 29 at 4:48 PM
$VRRM $ZS $LPCN $WOOF $LYFT How Iil ol LQQKER doin so far? Ya'll wealthier now too? 💰 5 for 5 so far, but w/more to come. 💋 💥 💥 💥 💥 💥 💥 💥 💥 💥 💥
1 · Reply
dbatech99
dbatech99 May. 28 at 11:46 AM
$LPCN I'd dump this, but even a 2 week old turd has more value at this point. This is officially the worst investment in history for me.
2 · Reply
LQQKER_INSIDER
LQQKER_INSIDER May. 27 at 7:38 PM
$VRRM $ZS $LPCN $WOOF $LYFT FOLLOW ME TO WEALTH. 💋 💋 💋 💋 💋
0 · Reply
Merlintrader
Merlintrader May. 27 at 12:07 PM
$LPCN Three Biotech Data Presentations to Watch: Precision BioSciences, Lipocine and Citius Oncology $DTIL $LPCN $CTOR https://www.merlintrader.com/biotech-data-presentations-may2026/
1 · Reply
focafoca99
focafoca99 May. 26 at 9:28 PM
$LPCN showcased Phase 3 data for LPCN 1154 in postpartum depression at the ASCP annual meeting.
1 · Reply
amazingcrwns
amazingcrwns May. 26 at 5:29 PM
$LPCN From the April 2nd press release: "Based on the results of the post hoc analysis of efficacy among participants with a history of psychiatric condition based on the MINI, the Company has applied for breakthrough therapy and fast track designations for LPCN 1154 in patients with PPD." I believe the FDA is supposed to respond to those applications in 60 days... so depending on when those were officially submitted, the company could hear back in the near future.
1 · Reply
amazingcrwns
amazingcrwns May. 26 at 12:53 PM
$LPCN Reminder, today Lipocine has an oral presentation at the ASCP Annual Meeting. The fact that they were selected for an oral presentation suggests to me that the outlier site explanation for the missed topline must be compelling. I don't think they would get more than a poster presentation if the consensus was a missed topline with a possible signal in a post hoc subgroup. I hope the presentation goes well, I'm sure Dr. Bruno will do a great job sharing the relevant results.
0 · Reply
BigTimePennyStocks
BigTimePennyStocks May. 25 at 8:08 PM
Small-Caps with Catalysts this week: 👇👇 ( $LPCN, $STSS, $ALP, $DGNX, etc...) #NASDAQ #NYSE
1 · Reply
LQQKER_INSIDER
LQQKER_INSIDER May. 21 at 6:53 PM
$LPCN Raise your hand ✋️ if you're the big dummy that sold me these shares today. 💋
0 · Reply
brunoq14
brunoq14 May. 21 at 4:38 PM
$LPCN Very optimistic. I just hope it doesn't take forever.
0 · Reply
agarfield
agarfield May. 20 at 9:05 PM
$LPCN good fireside, really comes down to how they handle the convo with the FDA. Even with the rogue clinic, the FDA is a tough negotiator on that front. I still cannot tell if they have a good relationship with the dept or not.
1 · Reply
LQQKER_INSIDER
LQQKER_INSIDER May. 20 at 8:10 PM
$LPCN NOTE: This is NOT an April Fools joke. 💋
0 · Reply